Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,127.25
(
0.47%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
101.12
(
2.86%
)
Bitcoin
74,464.95
(
-0.51%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 118983

Thursday, 04/28/2011 4:19:27 AM

Thursday, April 28, 2011 4:19:27 AM

Post# of 257253
SNY’s 1Q11 US Lovenox sales were down 5% to €222M (from €233M in 4Q10): http://en.sanofi-aventis.com/binaries/20110428_Q12011_en_tcm28-31968.pdf (page 15).

At the average exchange rate during 1Q11, the €222M translates into roughly $310M. Since NVS sold $247M of generic Lovenox in 1Q11, we now know that NVS had a 44% share of in-market dollar sales during the quarter, which is consistent with what NVS said on its 1Q11 CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now